New drugs for follicular lymphoma: mosunetuzumab and zeprumetostat
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests two new drugs combined together to treat follicular lymphoma (a slow-growing blood cancer). The trial enrolls patients who have never been treated, those with limited disease who want active treatment, and those whose cancer came back or didn't respond to prior therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Good enough overall health to tolerate treatment (ECOG score 0–2)
- Blood work and organ function within acceptable ranges
- Willingness to use effective birth control if able to have children
- Confirmed follicular lymphoma diagnosis, CD20-positive, no signs of transformation into aggressive lymphoma
- No prior treatment with CD20/CD3 bispecific antibodies or EZH2 inhibitors
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, mosunetuzumab, given as a shot under the skin for people with a slow-growing type of lymphoma (follicular lymphoma) that has not yet been treated and is not causing heavy symptoms or large tumor masses.
This trial tests a combination of two targeted drugs, mosunetuzumab and zanubrutinib, for people with follicular lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination is safe and effective.
This trial studies mosunetuzumab alone or combined with zanubrutinib to treat people with follicular lymphoma that is advanced or causing problems. It’s meant to see which approach works better and is safe for long-term treatment.
This Phase 2 study tests whether mosunetuzumab, added to lenalidomide, can treat people who have not yet received lymphoma medicines. It’s for follicular lymphoma or marginal zone lymphoma and may help shrink tumors and improve control of the disease.
This study tests a new combination of two drugs (mosunetuzumab and lenalidomide) compared to standard chemo-immunotherapy for people with newly diagnosed follicular lymphoma that needs treatment. It aims to see if the new combination works better and has fewer side effects.
This trial tests a combination of two drugs, Mosunetuzumab and Tislelizumab, for people with relapsed or refractory follicular lymphoma. The goal is to see if this combination can help when at least two prior treatments have stopped working.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.